Trials / Completed
CompletedNCT04342442
Identification of Novel Targetable Kinases in SR-a GvHD
Investigation of Novel Targetable Kinases in Steroid-refractory Acute Graft-versus-host Disease
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 24 (actual)
- Sponsor
- University of Freiburg · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
In this study, the investigators aim to identify novel targetable kinases in SR-a GvHD patient samples and investigate their role in different immune cell subtypes.
Detailed description
Corticosteroids are the first-line treatment of a GvHD, however many patients do not respond to corticosteroids. Patients with steroid-refractory a GvHD (SR-a GVHD) have a low 1-year survival rate. In this study, the investigators aim to identify and validate novel targetable kinases in SR-a GvHD patient peripheral blood mononuclear cells (PBMCs) by using a kinase-specific proteomic approach, and thereafter to investigate the role of the identified kinases in different immune cell subtypes by analyzing biopsies taken from SR- a GvHD patients.
Conditions
Timeline
- Start date
- 2017-01-01
- Primary completion
- 2019-12-31
- Completion
- 2019-12-31
- First posted
- 2020-04-13
- Last updated
- 2020-04-13
Source: ClinicalTrials.gov record NCT04342442. Inclusion in this directory is not an endorsement.